{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T19:50:03Z","timestamp":1771789803405,"version":"3.50.1"},"reference-count":66,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Hidradenitis suppurativa (HS) is a persistent, recurring skin inflammatory condition linked to various comorbidities. Management involves antibiotics, hormone therapy, immune-modulating drugs, surgery, and treatment of comorbidities. The objectives of the study were to assess the comorbidities, clinical presentation subtypes, and applied treatment of patients with HS. Methods: Patients with HS who visited the Centre of Dermatovenereology at Vilnius University Hospital Santaros Klinikos in Lithuania underwent evaluation based on the guidelines of the European Hidradenitis Suppurativa Foundation Registry questionnaire. Results: The study included 49 patients, and 61.22% (n = 30) had comorbidities. A strong positive correlation was found between a family history of inflammatory diseases (69.38% (n = 34)) and the severity of HS according to Hurley stage (r = 0.71 p &lt; 0.05). A statistically significant correlation (r = 0.944, p = 0.02) was found between metabolic comorbidities and Hurley stage. Patients on biologic treatment had a mean IHS4 of 7.38 at the beginning of treatment and 3.22 at follow-up (p &lt; 0.05). For patients not on biologics, the initial IHS4 score was 6.21 and 5.42 at follow-up (p &gt; 0.05). Conclusions: A family history of inflammatory diseases and metabolic comorbidities showed a strong correlation with HS severity. Treatment with biologics showed significant improvement in HS scores compared to systemic antibiotics.<\/jats:p>","DOI":"10.3390\/jcm13133900","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T04:23:43Z","timestamp":1719980623000},"page":"3900","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comorbidities, Clinical Presentation, Subtypes, and Treatment of HS Patients in Lithuania"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8852-1846","authenticated-orcid":false,"given":"Tadas","family":"Raudonis","sequence":"first","affiliation":[{"name":"Clinic of Infectious Disease and Dermatovenereology, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, M. K. \u010ciurlionio g. 21, 03101 Vilnius, Lithuania"},{"name":"European Hidradenitis Suppurativa Foundation e.V., 06847 Dessau, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3278-1960","authenticated-orcid":false,"given":"Aust\u0117ja","family":"\u0160akaityt\u0117","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Vilnius University, M. K. \u010ciurlionio g. 21, 03101 Vilnius, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas Petras","family":"Vileikis","sequence":"additional","affiliation":[{"name":"Clinic of Infectious Disease and Dermatovenereology, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, M. K. \u010ciurlionio g. 21, 03101 Vilnius, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7534-3787","authenticated-orcid":false,"given":"Vitalij","family":"\u010cernel","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Vilnius University, M. K. \u010ciurlionio g. 21, 03101 Vilnius, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u016bta","family":"Gancevi\u010dien\u0117","sequence":"additional","affiliation":[{"name":"Clinic of Infectious Disease and Dermatovenereology, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, M. K. \u010ciurlionio g. 21, 03101 Vilnius, Lithuania"},{"name":"European Hidradenitis Suppurativa Foundation e.V., 06847 Dessau, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos C.","family":"Zouboulis","sequence":"additional","affiliation":[{"name":"European Hidradenitis Suppurativa Foundation e.V., 06847 Dessau, Germany"},{"name":"Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, 06847 Dessau, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1080\/09546634.2021.1937484","article-title":"Pediatric hidradenitis suppurativa: Epidemiology, disease presentation, and treatments","volume":"33","author":"Seivright","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.jid.2020.10.014","article-title":"Unraveling the Heterogeneity of Hidradenitis Suppurativa with Phenotype Schema","volume":"141","author":"Kirby","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/AOG.0000000000004321","article-title":"Clinical Epidemiology and Management of Hidradenitis Suppurativa","volume":"137","author":"Sayed","year":"2021","journal-title":"Obs. Gynecol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jid.2018.01.009","article-title":"Hidradenitis Suppurativa Is Associated with Polycystic Ovary Syndrome: A Population-Based Analysis in the United States","volume":"138","author":"Garg","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/exd.14610","article-title":"Registries, multicentre and genome-wide association studies in hidradenitis suppurativa","volume":"31","author":"Jemec","year":"2022","journal-title":"Exp. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/bjd.20654","article-title":"Evidence of gene-gene interaction in hidradenitis suppurativa: A nationwide registry study of Danish twins","volume":"186","author":"Clemmensen","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jamadermatol.2020.3630","article-title":"Contribution of Genetics to the Susceptibility to Hidradenitis Suppurativa in a Large, Cross-sectional Dutch Twin Cohort","volume":"156","author":"Prens","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/jid.2012.472","article-title":"Identification of three hidradenitis suppurativa phenotypes: Latent class analysis of a cross-sectional study","volume":"133","author":"Revuz","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.jaad.2014.09.012","article-title":"Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: A chart-verified case-control analysis","volume":"71","author":"Shlyankevich","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/jdv.14517","article-title":"Recommendations for the management of comorbidity in hidradenitis suppurativa","volume":"32","author":"Dauden","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.12788\/j.sder.0093","article-title":"Recognizing and managing comorbidities and complications in hidradenitis suppurativa","volume":"33","author":"Menter","year":"2014","journal-title":"Semin. Cutan. Med. Surg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1001\/jamadermatol.2015.6264","article-title":"Risk of Major Adverse Cardiovascular Events and All-Cause Mortality in Patients with Hidradenitis Suppurativa","volume":"152","author":"Egeberg","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.5021\/ad.2016.28.2.147","article-title":"Management of Hidradenitis Suppurativa in Patients with Metabolic Comorbidities","volume":"28","author":"Lim","year":"2016","journal-title":"Ann. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.clindermatol.2017.09.007","article-title":"Hidradenitis suppurativa and the metabolic syndrome","volume":"36","author":"Ergun","year":"2018","journal-title":"Clin. Dermatol."},{"key":"ref_16","first-page":"46","article-title":"Hidradenitis suppurativa: Epidemiology, clinical features, associated comorbidities and treatment","volume":"152","author":"Shalom","year":"2017","journal-title":"G. Ital. Dermatol. Venereol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1001\/jamadermatol.2014.1165","article-title":"Association of Metabolic Syndrome and Hidradenitis Suppurativa","volume":"150","author":"Miller","year":"2014","journal-title":"JAMA Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1016\/j.jaad.2018.11.036","article-title":"Psoriasis and hidradenitis suppurativa: A large-scale population-based study","volume":"88","author":"Kridin","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4802","DOI":"10.3748\/wjg.v22.i20.4802","article-title":"Hydradenitis suppurativa and inflammatory bowel disease: An unusual, but existing association","volume":"22","author":"Principi","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/ijd.13932","article-title":"The in-hospital burden of hidradenitis suppurativa in patients with inflammatory bowel disease: A decade nationwide analysis from 2004 to 2014","volume":"57","author":"Timerman","year":"2018","journal-title":"Int. J. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"490","DOI":"10.3899\/jrheum.130977","article-title":"Hidradenitis Suppurativa Associated with Spondyloarthritis\u2014Results from a Multicenter National Prospective Study","volume":"41","author":"Richette","year":"2014","journal-title":"J. Rheumatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s13555-018-0264-z","article-title":"The Comorbidity Burden of Hidradenitis Suppurativa in the United States: A Claims Data Analysis","volume":"8","author":"Kimball","year":"2018","journal-title":"Dermatol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.det.2015.08.002","article-title":"Prevalence, Risk Factors, and Comorbidities of Hidradenitis Suppurativa","volume":"34","author":"Miller","year":"2016","journal-title":"Dermatol. Clin."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"491","DOI":"10.4103\/2229-5178.142517","article-title":"Follicular occlusion tetrad","volume":"5","author":"Vasanth","year":"2014","journal-title":"Indian. Dermatol. Online J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/ijd.13603","article-title":"Autoinflammatory syndromes associated with hidradenitis suppurativa and\/or acne","volume":"56","author":"Vinkel","year":"2017","journal-title":"Int. J. Dermatol."},{"key":"ref_26","first-page":"25","article-title":"Cutaneous squamous cell carcinoma complicating hidradenitis suppurativa: A review of the prevalence, pathogenesis, and treatment of this dreaded complication","volume":"27","author":"Chapman","year":"2018","journal-title":"Acta Dermatovenerol. Alp. Pannonica Adriat."},{"key":"ref_27","first-page":"21","article-title":"Adult Acne Versus Adolescent Acne","volume":"11","author":"Skroza","year":"2018","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1111\/ijd.14313","article-title":"Rethinking the female predominance in hidradenitis suppurativa","volume":"58","author":"Choi","year":"2019","journal-title":"Int. J. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000443878","article-title":"The ABC of Hidradenitis Suppurativa: A Validated Glossary on how to Name Lesions","volume":"232","author":"Lipsker","year":"2016","journal-title":"Dermatology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.det.2015.08.009","article-title":"Diagnosing Hidradenitis Suppurativa","volume":"34","author":"Revuz","year":"2016","journal-title":"Dermatol. Clin."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/1346-8138.14722","article-title":"Hidradenitis suppurativa of the nape: Description of an atypical phenotype related to severe early-onset disease in men","volume":"46","author":"Ribera","year":"2019","journal-title":"J. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/ijd.14210","article-title":"The clinical, biochemical, and ultrasonographic characteristics of patients with hidradenitis suppurativa in Northern Peninsular Malaysia: A multicenter study","volume":"57","author":"Loo","year":"2018","journal-title":"Int. J. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.jaad.2015.07.047","article-title":"New insights into the diagnosis of hidradenitis suppurativa: Clinical presentations and phenotypes","volume":"73","author":"Jemec","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1365-2133.2010.09773.x","article-title":"Questionnaire-based diagnosis of hidradenitis suppurativa: Specificity, sensitivity and positive predictive value of specific diagnostic questions","volume":"163","author":"Esmann","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/1203475415602840","article-title":"Clinical features and patient outcomes of hidradenitis suppurativa: A cross-sectional retrospective study","volume":"20","author":"Kim","year":"2016","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2340\/00015555-2815","article-title":"Clinical characteristics of pruritus and pain in patients with hidradenitis suppurativa","volume":"98","author":"Matusiak","year":"2018","journal-title":"Acta Derm.-Venereol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"42","DOI":"10.12788\/j.sder.2017.019","article-title":"Epidemiologic and clinical features of hidradenitis suppurativa","volume":"36","author":"Parulkar","year":"2017","journal-title":"Semin. Cutan. Med. Surg."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1111\/bjd.16603","article-title":"Profound consequences of hidradenitis suppurativa: A review","volume":"183","author":"Matusiak","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Smith, M.K., Nicholson, C.L., Parks-Miller, A., and Hamzavi, I.H. (2017). Hidradenitis Suppurativa: An Update on Connecting the Tracts. F1000Research, Available online: https:\/\/f1000research.com\/articles\/6-1272.","DOI":"10.12688\/f1000research.11337.1"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMcp1014163","article-title":"Hidradenitis Suppurativa","volume":"366","author":"Jemec","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0190-9622(98)70272-5","article-title":"Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa","volume":"39","author":"Jemec","year":"1998","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.jaad.2016.06.049","article-title":"Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): A case series","volume":"75","author":"Riis","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1365-2133.2006.07155.x","article-title":"Clindamycin and rifampicin combination therapy for hidradenitis suppurativa","volume":"154","author":"Griffiths","year":"2006","journal-title":"Br. J. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/jdv.12127","article-title":"Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa-acne inversa: A prospective study on 23 patients","volume":"28","author":"Bettoli","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000228334","article-title":"Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: A series of 116 consecutive patients","volume":"219","author":"Gener","year":"2009","journal-title":"Dermatology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000228337","article-title":"The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa","volume":"219","author":"Boer","year":"2009","journal-title":"Dermatology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","article-title":"Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: A parallel randomized trial","volume":"157","author":"Kimball","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2133.2011.10339.x","article-title":"A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa","volume":"165","author":"Miller","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","article-title":"Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled crossover trial","volume":"62","author":"Grant","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/rheumatology\/ker124","article-title":"Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis","volume":"50","author":"Plasencia","year":"2011","journal-title":"Rheumatology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease","volume":"348","author":"Baert","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaad.2016.10.042","article-title":"Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents","volume":"76","author":"Matusiak","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): Week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/exd.14338","article-title":"Target molecules for future hidradenitis suppurativa treatment","volume":"30","author":"Zouboulis","year":"2021","journal-title":"Exp. Dermatol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Liu, H., Santos, L.L., and Smith, S.H. (2023). Modulation of Disease-Associated Pathways in Hidradenitis Suppurativa by the Janus Kinase 1 Inhibitor Povorcitinib: Transcriptomic and Proteomic Analyses of Two Phase 2 Studies. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24087185"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Shukla, R., Karagaiah, P., Patil, A., Farnbach, K., Ortega-Loayza, A.G., Tzellos, T., Szepietowski, J.C., Giulini, M., Schepler, H., and Grabbe, S. (2022). Surgical Treatment in Hidradenitis Suppurativa. J. Clin. Med., 11.","DOI":"10.3390\/jcm11092311"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1524-4725.2011.02186.x","article-title":"Hidradenitis suppurativa: Surgical and other management techniques","volume":"38","author":"Ellis","year":"2012","journal-title":"Dermatol. Surg."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00268-008-9845-9","article-title":"Surgical approach to extensive hidradenitis suppurativa in the perineal\/perianal and gluteal regions","volume":"33","author":"Balik","year":"2009","journal-title":"World J. Surg."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1097\/DSS.0000000000000806","article-title":"Surgical Management of Hidradenitis Suppurativa: Outcomes of 590 Consecutive Patients","volume":"42","author":"Kohorst","year":"2016","journal-title":"Dermatol. Surg."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.jaad.2015.07.043","article-title":"New and traditional surgical approaches to hidradenitis suppurativa","volume":"73","author":"Danby","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0039-6109(02)00060-9","article-title":"Hidradenitis suppurativa","volume":"82","author":"Mitchell","year":"2002","journal-title":"Surg. Clin. N. Am."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Alharbi, Z., Kauczok, J., and Pallua, N. (2012). A review of wide surgical excision of hidradenitis suppurativa. BMC Dermatol., 12.","DOI":"10.1186\/1471-5945-12-9"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1046\/j.1524-4725.2000.00043.x","article-title":"Long-term results of wide surgical excision in 106 patients with hidradenitis suppurativa","volume":"26","author":"Rompel","year":"2000","journal-title":"Dermatol. Surg."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/SAP.0000000000000584","article-title":"Outcomes After Combined Radical Resection and Targeted Biologic Therapy for the Management of Recalcitrant Hidradenitis Suppurativa","volume":"77","author":"DeFazio","year":"2016","journal-title":"Ann. Plast. Surg."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1365-2133.2012.10807.x","article-title":"Treatment of severe hidradenitis suppurativa with infliximab in combination with surgical interventions","volume":"167","author":"Mekkes","year":"2012","journal-title":"Br. J. Dermatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/13\/3900\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:09:26Z","timestamp":1760108966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/13\/3900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,3]]},"references-count":66,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["jcm13133900"],"URL":"https:\/\/doi.org\/10.3390\/jcm13133900","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,3]]}}}